DK0842947T3 - Hepatitis C-virus-asialoglycoproteiner - Google Patents

Hepatitis C-virus-asialoglycoproteiner

Info

Publication number
DK0842947T3
DK0842947T3 DK97120661T DK97120661T DK0842947T3 DK 0842947 T3 DK0842947 T3 DK 0842947T3 DK 97120661 T DK97120661 T DK 97120661T DK 97120661 T DK97120661 T DK 97120661T DK 0842947 T3 DK0842947 T3 DK 0842947T3
Authority
DK
Denmark
Prior art keywords
virus
proteins
hepatitis
hcv
recombinant
Prior art date
Application number
DK97120661T
Other languages
English (en)
Other versions
DK0842947T4 (da
Inventor
Robert O Ralston
Frank Marcus
Kent B Thudium
Barbara A Gervase
John A Hall
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0842947(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DK0842947T3 publication Critical patent/DK0842947T3/da
Application granted granted Critical
Publication of DK0842947T4 publication Critical patent/DK0842947T4/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK97120661T 1990-11-08 1991-11-07 Hepatitis C-virus-asialoglycoproteiner DK0842947T4 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61196590A 1990-11-08 1990-11-08
US61141990A 1990-11-08 1990-11-08
US75888091A 1991-09-13 1991-09-13
PCT/US1991/008272 WO1992008734A1 (en) 1990-11-08 1991-11-07 Hepatitis c virus asialoglycoproteins
EP92900091A EP0556292B2 (en) 1990-11-08 1991-11-07 Hepatitis c virus asialoglycoproteins

Publications (2)

Publication Number Publication Date
DK0842947T3 true DK0842947T3 (da) 2004-07-26
DK0842947T4 DK0842947T4 (da) 2009-06-08

Family

ID=27417050

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97120661T DK0842947T4 (da) 1990-11-08 1991-11-07 Hepatitis C-virus-asialoglycoproteiner
DK92900091T DK0556292T4 (da) 1990-11-08 1991-11-07 Hepatitis C virus asialoglycoproteiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK92900091T DK0556292T4 (da) 1990-11-08 1991-11-07 Hepatitis C virus asialoglycoproteiner

Country Status (17)

Country Link
EP (2) EP0842947B2 (da)
JP (8) JPH06504431A (da)
AT (1) ATE188220T1 (da)
AU (1) AU668078B2 (da)
CA (2) CA2203443C (da)
CZ (1) CZ289006B6 (da)
DE (1) DE69131882T3 (da)
DK (2) DK0842947T4 (da)
ES (1) ES2139591T5 (da)
FI (1) FI107803B (da)
GR (1) GR3032771T3 (da)
HU (2) HUT66063A (da)
NO (2) NO304380B1 (da)
PT (2) PT99466B (da)
RO (1) RO115446B1 (da)
SK (3) SK286106B6 (da)
WO (1) WO1992008734A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 C型肝炎診断薬
JP3439209B2 (ja) * 1992-01-31 2003-08-25 アボツト・ラボラトリーズ Hcv蛋白のための哺乳動物発現システム
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
WO1994026306A1 (en) * 1993-05-12 1994-11-24 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
ES2174957T5 (es) 1994-07-29 2006-12-16 Innogenetics N.V. Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
DE69534296T2 (de) 1994-07-29 2006-04-27 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Sezernierter E1/E2-Komplex des Hepatitis C-Virus, des aus C-terminal verkürzten Polypeptiden E1 und E2 erhalten ist
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
FR2744725B1 (fr) * 1996-02-09 1998-04-30 Pasteur Institut Anticorps specifiques des complexes formes par les glycoproteines e1 et e2 du virus de l'hepatite c, procedes de determination de la presence, et d'isolement de ces complexes
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
KR100209095B1 (ko) 1996-06-28 1999-07-15 성재갑 C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
DE69841015D1 (de) 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
JP5175417B2 (ja) 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
EP1551960A4 (en) * 2002-08-16 2006-02-01 Univ Ohio CLEANING HEPATITIS C VIRUS SIMILAR PARTICLE
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US20090214593A1 (en) 2007-08-16 2009-08-27 Tripep Ab Immunogen platform

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン コーポレイション Nanbvの診断用薬およびワクチン
IL88599A0 (en) * 1987-12-10 1989-07-31 Cell Bio Group Ltd Glycoprotein cell growth modulating materials,their preparation and compositions containing them
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
HU217025B (hu) * 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben

Also Published As

Publication number Publication date
DE69131882T2 (de) 2000-05-04
SK285623B6 (sk) 2007-05-03
NO931680L (no) 1993-06-28
PT102022A (pt) 1999-01-29
WO1992008734A1 (en) 1992-05-29
AU9026791A (en) 1992-06-11
PT99466A (pt) 1992-10-30
CA2203443C (en) 2001-08-28
EP0556292A4 (da) 1995-01-18
CA2095521C (en) 2009-06-30
GR3032771T3 (en) 2000-06-30
EP0842947B2 (en) 2009-03-18
EP0842947A2 (en) 1998-05-20
RO115446B1 (ro) 2000-02-28
PT102022B (pt) 2000-12-29
NO304380B1 (no) 1998-12-07
NO304381B1 (no) 1998-12-07
EP0842947B1 (en) 2004-04-21
FI107803B (fi) 2001-10-15
PT99466B (pt) 1999-04-30
JP3207155B2 (ja) 2001-09-10
JP2003093081A (ja) 2003-04-02
EP0556292B1 (en) 1999-12-29
ES2139591T5 (es) 2007-08-01
FI932025A0 (fi) 1993-05-05
JPH06504431A (ja) 1994-05-26
CA2203443A1 (en) 1992-05-09
CA2095521A1 (en) 1992-05-09
DE69131882D1 (en) 2000-02-03
ES2139591T3 (es) 2000-02-16
JP2006219503A (ja) 2006-08-24
SK69097A3 (en) 1997-11-05
JP2001286290A (ja) 2001-10-16
EP0842947A3 (en) 2001-12-12
DK0556292T3 (da) 2000-04-17
FI932025L (fi) 1993-06-07
JP2005187479A (ja) 2005-07-14
JP2008031181A (ja) 2008-02-14
JP2003174875A (ja) 2003-06-24
HU227498B1 (en) 2011-07-28
NO931680D0 (no) 1993-05-07
SK286106B6 (sk) 2008-03-05
SK285624B6 (sk) 2007-05-03
JPH1171395A (ja) 1999-03-16
DE69131882T3 (de) 2007-05-24
ATE188220T1 (de) 2000-01-15
CZ82493A3 (en) 1994-04-13
SK44293A3 (en) 1993-08-11
HUT66063A (en) 1994-09-28
CZ289006B6 (cs) 2001-10-17
HU9301336D0 (en) 1993-10-28
DK0556292T4 (da) 2006-12-27
AU668078B2 (en) 1996-04-26
NO972213D0 (no) 1997-05-14
EP0556292A1 (en) 1993-08-25
NO972213L (no) 1997-05-14
DK0842947T4 (da) 2009-06-08
EP0556292B2 (en) 2006-11-29
JP4056306B2 (ja) 2008-03-05

Similar Documents

Publication Publication Date Title
DK0556292T3 (da) Hepatitis C virus asialoglycoproteiner
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
PT989999E (pt) Composicao anti-tumoral a base de polipeptido imunogenico de localizacao celular modificada
FI941199A0 (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
ATE423204T1 (de) Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
DE69535018D1 (de) Papillomavirus vakzine
CA2056437A1 (en) Production of virus and purification of viral envelope proteins for vaccine use
AU7234987A (en) Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody
FR2445338A1 (fr) Preparation de glycoproteine isolee d'enveloppes d'onco-rna virus et vaccins qui la contiennent
EP0216564A3 (en) Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
PT586076E (pt) Vacinas de adenovirus recombinantes
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
EP1471073A3 (en) Hepatitis C virus asialoglycoproteins
FI971702L (fi) Hepatiitti-C-viruksen asialoglykoproteiinit
KR880003971A (ko) 재조합 바쿨로비루스 벡터로 부터 b형 간염비루스 항원의 발현
KR890701745A (ko) O-결합 글리코실화가 감소된 바이러스 단백질
EP0385394A3 (en) Polyhedrin gene and genetic engineering thereof
EP0234862A3 (en) Expression of recombinant proteins in yeast